Excellent review in to biology of CRS and ICANS by Prof Emma Morris 💙 and colleagues. Worth a read by anyone using adoptive immunotherapy 👏👏

The #haematology and critical care services in our University College Hospital Grafton Way Building are now open. With nearly 100 beds dedicated to haematology patients at UCLH, this is one of the largest centres in Europe. Photo credit: Paul Raftery buff.ly/3KxA2zv

Are you trying to advance your #hematology research? #CRTH lets early-career researchers build #clinicaltrial skills in running & expand professional networks. Learn about Selina Chavda's CRTH journey 👇. Applications for CRTH are open until November 15: eha.fyi/CRTH22

Presenting a new “CAR Pooling” technique, Daniel Bryan Goodman, Kole Roybal, and co. comb through domains from various immune lineages to build new #CARTCell designs and identify several that boost anticancer efficacy against #MultipleMyeloma in mice. Parker Institute for Cancer Immunotherapy scim.ag/xD

We’re looking for a Haematology Clinical Fellow to join our early phase cancer trials programme UCLH. If you want cutting edge clinical trials experience in myeloma, lymphoma, AML & MDS take a look👇 Jen O bit.ly/3U1uvEP

Patients from lower socioeconomic class are less likely to be enrolled into myeloma clinical trials. Something we need to fix if trials are to be representative of the populations we serve. Poster by Amrutha Sridhar Selina Chavda UCLH NIHR UCLH Biomedical Research Centre #IMS23

Our commentary on the GRIFFIN and APOLLO trials and their implications for multiple myeloma Selina Chavda #mmsm thelancet.com/journals/lanha…

This paper addresses many of the “best practices” we believe will help reduce disparities in myeloma in the African American community. Thanks so much to all coauthors! #imfmpower

Very pleased that #EBMT24 raised the profile of equity & access. Fantastic audience engagement with comments/ questions.

My Annual Updated Myeloma Treatment Algorithms thread. Bookmark! #ASH24 #ASH24VR 1. Newly diagnosed transplant ineligible. Quadruplet unless frail. Maintenance varies by risk stratification.

Understanding barriers to enrolment into clinical trials in the UK. Results of a national survey of healthcare professionals and patients. Selina Chavda Sandra Quinn (PhD) Chantelle Hughes RN Dr Pinkie Chambers #ASH24 #mmsm

A opportunity to join our research team - Haematology trainees interested in plasma cell disorders - DM if interested UK Myeloma Society BSH - Haematology ASH